Related Experiment Video
Updated: Jun 14, 2026

09:03
Trabecular Meshwork Response to Pressure Elevation in the Living Human Eye
Published on: June 20, 2015
9.9K
Prototype master protocol for benchmarking of real-world follow-up data in glaucoma
Pekko Hujanen1,2, Anja Tuulonen1, Sanna Leinonen1,2
1Tays Eye Centre, Tampere University Hospital, Tampere, Finland.
Acta Ophthalmologica
|February 13, 2025
Summary
This study developed a master protocol for benchmarking glaucoma real-world data (RWD). Glaucoma progression rates in Finland were comparable to published data, highlighting the need for standardized RWD analysis.
Area of Science:
- Ophthalmology
- Health Informatics
- Data Science
Background:
- Real-world data (RWD) is crucial for understanding glaucoma progression and treatment effectiveness.
- Standardized methods are needed to benchmark glaucoma RWD across different healthcare systems.
- The Finnish aces-rwm ecosystem aims to improve care through digital innovation and RWD monitoring.
Purpose of the Study:
- To create a prototype master protocol for benchmarking glaucoma RWD.
- To establish a framework for comparing glaucoma patient data across institutions.
- To support the Finnish aces-rwm digital innovation strategy.
Main Methods:
- Collected glaucoma RWD from Tampere University Hospital (Tays) between 2012-2017.
- Compared Tays data with six published RWD sets from Sweden and England.
- Analyzed visual field (VF) and mean deviation (MD) data, considering age and intraocular pressure (IOP).
Main Results:
- Higher age correlated with faster glaucoma progression in most datasets.
- Glaucoma progression rates at Tays were comparable to a published English RWD trial.
- Significant variability exists in the reporting of findings across published glaucoma RWD datasets.
Conclusions:
- This study is a foundational step towards a master protocol for benchmarking glaucoma care using RWD.
- Further protocol refinement requires national and international collaboration.
- Developing comparable RWD sets is essential for advancing glaucoma research and care.

